Back to News
Market Impact: 0.2
Autonomix Medical Receives European Patent For Neural Activity Assessment Technology
Source: Nasdaq
Patents & Intellectual PropertyHealthcare & BiotechTechnology & Innovation
Autonomix Medical (AMIX) received European Patent No. EP 4 233 700 B1 for systems assessing neural activity in the eye. The patent expands European intellectual-property protection for the company’s autonomic nervous system assessment and precision neuromodulation technologies, a modest positive for its technology platform.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
AMIX0.60
More News
- Key AI chip index just broke its long-term trendline. What history says happens next
- Banks, investors grow wary of AI debt, spooked by market selloff
- Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
- Why is Nvidia’s Jensen Huang at the centre of a US-China spy scandal?
- CoreWeave confronts 'doom cycle' narrative as neocloud credit risk overshadows growth
- Bon Secours affiliate sweetens bid for Surgery Partners to up to $6 billion